Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q2 2021 Results - Earnings Call Transcript

Aug. 04, 2021 10:46 PM ETPacira BioSciences, Inc. (PCRX)
SA Transcripts profile picture
SA Transcripts

Flexion Therapeutics, Inc. (FLXN) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET

Company Participants

Scott Young - Vice President, Corporate Communications and Investor Relations

Michael Clayman - Chief Executive Officer

Melissa Layman - Chief Commercial Officer

Fred Driscoll - Chief Financial Officer

Conference Call Participants

Michael Pagliari - Raymond James

Madhu Kumar - Goldman Sachs

Daniel Busby - RBC Capital Markets

Evan Hua - BMO Capital Markets

Serge Belanger - Needham & Company

Patrick Trucchio - H.C. Wainwright

Daniel Brennan - Oppenheimer


Good afternoon, ladies and gentlemen and welcome to the Flexion Therapeutics Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session at the end of today's call. [Operator Instructions]

I'll now turn the call over to Scott Young, Flexion Vice President of Corporate Communications and Investor Relations.

Scott Young

Good afternoon. A short while ago, we issued a press release announcing our second quarter financial results. That press release and our latest Commercial Metrics Slides can be found under the Investors tab on the company's website. And a replay of this call will be accessible there shortly after its conclusion.

Today's discussion will be led by Flexion's Chief Executive Officer, Dr. Michael Clayman; and he's joined by Melissa Layman, Flexion's Chief Commercial Officer; and Fred Driscoll, Flexion's Chief Financial Officer.

On today's conference call, we will be making statements relating to future financial and business performance, market conditions, strategies and other business matters, including expectations regarding revenue, cash utilization, clinical, regulatory and commercial developments and anticipated milestones, which are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are subject to various assumptions, risks and uncertainties, which change over time.

And such statements speak

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.